NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.11) earnings per share for the quarter, Zacks reports.
NeuroSense Therapeutics Stock Up 12.3 %
Shares of NeuroSense Therapeutics stock opened at $1.28 on Friday. The company has a market capitalization of $17.49 million, a P/E ratio of -1.51 and a beta of 1.38. The company has a 50 day moving average of $1.12 and a 200 day moving average of $1.03. NeuroSense Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.33.
Analyst Ratings Changes
Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a research report on Monday.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.
See Also
- Five stocks we like better than NeuroSense Therapeutics
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Palantir’s Momentum Persists Despite Market Worries
- Consumer Discretionary Stocks Explained
- Ad Sales to Top $1 Trillion: 3 Stocks to Take Advantage
- What Are Some of the Best Large-Cap Stocks to Buy?
- Micron Stock Under $100: Seize the AI-Driven Upside
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
